Streetbeat News

Products Services

LYFT

Lyft has introduced a new feature called Women+ Connect, which prioritizes matches between women and nonbinary drivers and riders. The feature will initially roll out in select US cities including Chicago, Phoenix, San Diego, San Francisco, and San Jose. Lyft CEO David Risher stated that the feature aims to provide more earning opportunities for women and nonbinary people and give riders more choice.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:37 pm

ASTI

GDDY

LYRA

Ascent Solar Technologies (ASTI) has achieved a new benchmark of 15.5% in cell production efficiency of its CIGS solar technology. Lyra Therapeutics' (LYRA) BEACON Phase 2 study of LYR-220 for chronic rhinosinusitis in patients with prior ethmoid sinus surgery met its primary endpoint. GoDaddy (GDDY) shares are trading higher after Starboard Value sent a letter to the company, stating it believes GoDaddy is deeply undervalued with significant opportunities for shareholder value creation.

Portfolio Pulse from ryanfaloona@benzinga.com

September 12, 2023 | 12:35 pm

ABBV

AbbVie has announced positive topline results from its Phase 3 SEQUENCE trial of Skyrizi (Risankizumab) versus Stelara (Ustekinumab). The study met its primary endpoint in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:34 pm

VTGN

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company, announced that PH80, one of its investigational neuroactive nasal sprays, showed statistically significant improvement versus placebo in a Phase 2A study for acute management of the symptoms of premenstrual dysphoric disorder (PMDD).

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:33 pm

ENTX

OPK

Entera Bio Ltd. (ENTX) and OPKO Biologics, a subsidiary of OPKO Health, Inc. (OPK), have entered into a Research Collaboration Agreement. OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin (OXM) analogs for the development of oral tablet formulations using Entera's proprietary oral delivery technology.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:33 pm

BRTX

BioRestorative Therapies has announced an initial order of 5,000 vials of its product, which it describes as a controlled launch. The company expects this to have a positive financial impact.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:32 pm

FLT

Corpay has launched Payments GPS, a new feature that provides real-time status updates on cross-border payments. This new feature is expected to usher in a new era of payment transparency.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:32 pm

BRTX

BioRestorative Therapies Inc (NASDAQ:BRTX) has entered into a supply agreement with Evolutionary Biologics to manufacture tissue-based biologics for cosmetic and aesthetic applications. The initial order of 5,000 vials is expected to have a positive financial impact. The first product is an umbilical cord tissue extract enriched with factors that address signs of aging. Evolutionary Biologics, founded by former L'Oreal President Jim Morrison, supplies cosmetic-focused biologics to plastic surgeons, dermatologists, and medical spas in the U.S.

Portfolio Pulse from Vandana Singh

September 12, 2023 | 12:30 pm

XOS

Xos, a manufacturer of electric vehicles, has been awarded a contract by the State of California to provide electric stepvans to state and local agencies. The financial details of the contract were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 12:28 pm

SLRN

Acelyrin Inc (NASDAQ:SLRN) announced topline results from a Phase 2b/3 trial evaluating izokibep for moderate-to-severe Hidradenitis Suppurativa (HS). The primary endpoint did not meet statistical significance, but showed early responses and no safety issues. The stock price fell by 58.80% in premarket trading.

Portfolio Pulse from Vandana Singh

September 12, 2023 | 12:28 pm